The burden of atherosclerotic cardiovascular disease (ASCVD) in high-income countries is mostly borne by the elderly. With increasing life expectancy, clear guidance on sensible use of statin therapy to prevent a first and potentially devastating ASCVD event is critically important to ensure a healthy aging population. Since 2013, 5 major North American and European guidelines on statin use in primary prevention of ASCVD have been released by the American College of Cardiology/American Heart Association, the UK National Institute for Health and Care Excellence, the Canadian Cardiovascular Society, U.S. Preventive Services Task Force, and the European Society of Cardiology/European Atherosclerosis Society. Guidance on using statin therapy in primary ASCVD prevention in the growing elderly population (>65 years of age) differs markedly. The authors discuss the discrepant recommendations, place them into the context of available evidence, and identify circumstances in which uncertainty may hamper the appropriate use of statins in the elderly.

中文翻译：

---

老年人使用他汀类药物的一级预防

高收入国家动脉粥样硬化性心血管疾病（ASCVD）的负担主要由老年人承担。随着预期寿命的增加，明确指导合理使用他汀类药物治疗以预防首次和潜在的破坏性 ASCVD 事件对于确保健康的老龄化人口至关重要。自 2013 年以来，美国心​​脏病学会/美国心脏协会、英国国家健康与护理卓越研究所、加拿大心血管学会、美国预防服务机构发布了 5 项北美和欧洲关于他汀类药物用于 ASCVD 一级预防的主要指南工作组和欧洲心脏病学会/欧洲动脉粥样硬化学会。在不断增长的老年人群（> 65 岁）中使用他汀类药物进行 ASCVD 一级预防的指南存在显着差异。